68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Biopsy-confirmed adenocarcinoma of the prostate.
No anti-tumor treatment received prior to the PET imaging.
Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.
Radical prostatectomy scheduled within 28 days after PET imaging.
Patients with other malignant tumors
Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.